Search Results - "Voges, Y"

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells by Michaelis, M, Rothweiler, F, Barth, S, Cinatl, J, van Rikxoort, M, Löschmann, N, Voges, Y, Breitling, R, von Deimling, A, Rödel, F, Weber, K, Fehse, B, Mack, E, Stiewe, T, Doerr, H W, Speidel, D, Cinatl, J

“…Six p53 wild-type cancer cell lines from infrequently p53-mutated entities (neuroblastoma, rhabdomyosarcoma, and melanoma) were continuously exposed to…”
Get full text

Flubendazole as potential anti-neuroblastoma therapy option by Michaelis, M, Agha, B, Rothweiler, F, Loeschmann, N, Voges, Y, Westermann, F, Wass, M, Cinatl, J

“…An abstract of a study by Michaelis et al on flubendazole as potential anti-neuroblastoma therapy option is presented. The study tested flubendazole for…”
Get full text

Flubendazole as potential anti-neuroblastoma therapy option by Michaelis, M, Agha, B, Florian, R, Löschmann, N, Voges, Y, Westermann, F, Wass, M, Cinatl, J

Get full text

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents by Michaelis, M, Rothweiler, F, Agha, B, Barth, S, Voges, Y, Löschmann, N, von Deimling, A, Breitling, R, Wilhelm Doerr, H, Rödel, F, Speidel, D, Cinatl, J

“…Adaptation of wild-type p53 expressing UKF-NB-3 cancer cells to the murine double minute 2 inhibitor nutlin-3 causes de novo p53 mutations at high frequency…”
Get full text

126 - Flubendazole as potential anti-neuroblastoma therapy option by Michaelis, M., Agha, B., Rothweiler, F., Loeschmann, N., Voges, Y., Westermann, F., Wass, M., Cinatl, J.

Get full text

553 - Flubendazole as potential anti-neuroblastoma therapy option by Michaelis, M., Agha, B., Florian, R., Löschmann, N., Voges, Y., Westermann, F., Wass, M., Cinatl, J.

Get full text